Long‐term benefits of single‐dose psilocybin in depressed patients with cancer

Thu, Jun 19

Perspectives

Psilocybin in depressed cancer patients: 'robust antidepressive activity from a single 25 mg dose of psilocybin combined with psychotherapy and suggest a potentially paradigm-changing alternative to traditional antidepressants' benefit lasted 2 years https://t.co/RDsFsBX0Op

6232

A phase 2 trial demonstrated safety, feasibility, and efficacy of a single 25-mg dose of psilocybin combined with psychological support in a community cancer setting in patients with cancer and a...

Discover